Baseline clinical characteristics according to randomization groups
| Baseline characteristics . | 6 wk of LMWH (n = 15) . | 3 wk of LMWH followed by 3 wk of ASA (n = 15) . |
|---|---|---|
| Maternal age (y), median (IQR) | 33.5 (32.6-39.0) | 33.2 (28.7-34.6) |
| Inclusion criteria | ||
| Previous unprovoked VTE or provoked VTE before not prescribed extended therapeutic anticoagulation, n (%) | 15 (100.0) | 14 (93.3) |
| Compound heterozygote or homozygous for FVL mutation or PGM and family history, n (%) | 0 (0.0) | 1 (6.7) |
| Ethnicity, n (%) | ||
| White | 13 (86.7) | 8 (53.3) |
| Hispanic | 0 (0.0) | 1 (6.7) |
| Black | 1 (6.7) | 2 (13.3) |
| Mixed race | 0 (0.0) | 1 (6.7) |
| Asian (South, Middle East, mixed) | 1 (6.7) | 3 (20.0) |
| BMI, kg/m2∗ | ||
| Median (IQR) | 35.4 (26.9-39.0) | 32.3 (28.7- 33.2) |
| >24, n (%) | 14 (93.3) | 14 (93.3) |
| >30, n (%) | 10 (73.3) | 11 (73.3) |
| >40, n (%) | 3 (20.0) | 1 (6.7) |
| Primigravity, n (%) | 7 (46.7) | 5 (33.3) |
| Gestational age at randomization (wk), median (IQR) | 33.5 (32.2-36.6) | 34.3 (31.3-36.0) |
| Use of ASA antenatally, n (%) | 6 (40.0) | 5 (33.3) |
| Median time since previous VTE, y (IQR) | 10.0 (4-11) | 3 (2-7) |
| Location of previous VTA | ||
| PE with or without DVT, n (%) | 10 (66.6) | 4 (26.7) |
| Upper or lower extremity DVT only, n (%) | 4 (26.7) | 11 (73.3) |
| Cerebral vein thrombosis | 1 (6.7) | 0 (0) |
| Provoking factors of previous VTE, n (%) | ||
| Hormonal contraception or assisted reproduction | 6 (40.0) | 4 (26.7) |
| Unprovoked | 6 (40.0) | 3 (20.0) |
| Postpartum (up to 12 wk) | 1 (6.7) | 3 (20.0) |
| Pregnancy (antepartum) associated VTE | 2 (13.3) | 4 (26.7) |
| Air travel† | 2 (13.3) | 1 (6.7) |
| Known thrombophilia | 1 (6.7) | 1 (6.7) |
| Baseline characteristics . | 6 wk of LMWH (n = 15) . | 3 wk of LMWH followed by 3 wk of ASA (n = 15) . |
|---|---|---|
| Maternal age (y), median (IQR) | 33.5 (32.6-39.0) | 33.2 (28.7-34.6) |
| Inclusion criteria | ||
| Previous unprovoked VTE or provoked VTE before not prescribed extended therapeutic anticoagulation, n (%) | 15 (100.0) | 14 (93.3) |
| Compound heterozygote or homozygous for FVL mutation or PGM and family history, n (%) | 0 (0.0) | 1 (6.7) |
| Ethnicity, n (%) | ||
| White | 13 (86.7) | 8 (53.3) |
| Hispanic | 0 (0.0) | 1 (6.7) |
| Black | 1 (6.7) | 2 (13.3) |
| Mixed race | 0 (0.0) | 1 (6.7) |
| Asian (South, Middle East, mixed) | 1 (6.7) | 3 (20.0) |
| BMI, kg/m2∗ | ||
| Median (IQR) | 35.4 (26.9-39.0) | 32.3 (28.7- 33.2) |
| >24, n (%) | 14 (93.3) | 14 (93.3) |
| >30, n (%) | 10 (73.3) | 11 (73.3) |
| >40, n (%) | 3 (20.0) | 1 (6.7) |
| Primigravity, n (%) | 7 (46.7) | 5 (33.3) |
| Gestational age at randomization (wk), median (IQR) | 33.5 (32.2-36.6) | 34.3 (31.3-36.0) |
| Use of ASA antenatally, n (%) | 6 (40.0) | 5 (33.3) |
| Median time since previous VTE, y (IQR) | 10.0 (4-11) | 3 (2-7) |
| Location of previous VTA | ||
| PE with or without DVT, n (%) | 10 (66.6) | 4 (26.7) |
| Upper or lower extremity DVT only, n (%) | 4 (26.7) | 11 (73.3) |
| Cerebral vein thrombosis | 1 (6.7) | 0 (0) |
| Provoking factors of previous VTE, n (%) | ||
| Hormonal contraception or assisted reproduction | 6 (40.0) | 4 (26.7) |
| Unprovoked | 6 (40.0) | 3 (20.0) |
| Postpartum (up to 12 wk) | 1 (6.7) | 3 (20.0) |
| Pregnancy (antepartum) associated VTE | 2 (13.3) | 4 (26.7) |
| Air travel† | 2 (13.3) | 1 (6.7) |
| Known thrombophilia | 1 (6.7) | 1 (6.7) |